A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer

Stopped early · Phase 2

Conditions studied: Metastatic Breast Cancer

In brief

This is a Phase 2, multicenter, open-label, noncomparative study to evaluate safety,efficacy and of single-agent EZN 2208 administered in patients with previously treated MBC. After discontinuation of study treatment, patients will receive care as considered appropriate by the investigator. Patients will continue to be followed for disease progression, subsequent anticancer therapy, and survival.

Key facts

Study ID

NCT01036113

Run by

Enzon Pharmaceuticals, Inc.

People needed

160

Starts

2009-11-01

Expected to finish

2012-12-01

Last updated by the study team

2022-02-14

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed breast adenocarcinoma that is metastatic. Receptor status of the tumor must be known.
• Disease progression during or after immediate previous therapy, or intolerable toxicity leading to cessation of immediate previous therapy
• Previous treatment for MBC:
• AT Cohort: Prior AT required as adjuvant or metastatic therapy; no more than 2 prior chemotherapy regimens for MBC.
• ATX Cohort: Prior ATX required as adjuvant or metastatic therapy;no more than 4 prior chemotherapy regimens for MBC.
• For patients with positive receptor status:
• Patients with HER2+ MBC must have received prior trastuzumab.
• Patients with ER+ MBC must have received prior hormone therapy.
• Measurable disease by RECIST Version 1.1
• Women 18 years or older
• ECOG performance status of 0 to 2
• Adequate bone marrow, renal and hepatic functions

You may not qualify if…

• Major surgery within 3 weeks before study start
• Known or suspected brain metastases requiring intervention with steroids and/or radiation therapy
• Prior chemotherapy, immunotherapy, non-investigational agent, or other therapy used to treat the cancer within 3 weeks before scheduled administration of EZN-2208
• History of other primary cancer within 5 years of enrollment, unless
• Curatively resected non-melanomatous skin cancer, or
• Curatively resected cervical cancer
• Lack of recovery to Grade 1 from any reversible side effects related to the administration of an investigational agent, chemotherapy, or other prior treatments for the cancer
• Current participation in another clinical study with an investigational agent and/or use of an investigational drug (not including investigational use of an approved drug) in the 30 days before the first administration of EZN-2208
• Known chronic infectious disease, such as AIDS

Where it is running

• Location #12 — Sedona, Arizona, United States
• Location #5 — Tucson, Arizona, United States
• Location #32 — Murrieta, California, United States
• Location #39 — Oxnard, California, United States
• Location #18 — Denver, Colorado, United States
• Location #36 — New Port Richey, Florida, United States
• Location #1 — Ocoee, Florida, United States
• Location #40 — Niles, Illinois, United States
• Location #15 — Carmel, Indiana, United States
• Location #10 — Minneapolis, Minnesota, United States
• Location #16 — Columbia, Missouri, United States
• Location #14 — Kansas City, Missouri, United States
• Location #2 — Henderson, Nevada, United States
• Location#19 — Troy, New York, United States
• Location #4 — Raleigh, North Carolina, United States
• Location #41 — Columbus, Ohio, United States
• Location #27 — Portland, Oregon, United States
• Location #8 — Greenville, South Carolina, United States
• Location #33 — Abilene, Texas, United States
• Location #34 — Arlington, Texas, United States
• Location #9 — Austin, Texas, United States
• Location #3 — Bedford, Texas, United States
• Location #26 — Dallas, Texas, United States
• Location #13 — Dallas, Texas, United States
• Location #30 — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.